You are here

Share:

News

May 25th Tech Opportunity Webinar: CytoSig, a Novel Software Platform Predictor of Cytokine Signaling Activity & Targeted Discovery

May 11, 2022

Date & Time: Wednesday, May 25th, 11am-12pm ET

REGISTER

Join us for a TTC-hosted webinar and hear from NCI’s Dr. Peng Jiang about a new Cytokine Signaling Analyzer called “CytoSig.” This novel software-based platform provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. CytoSig covers 20,591 curated human cytokine, chemokine, and growth factor response experiments, and can reliably predict the activity of 43 cytokines in both tissues and single cells based on the transcriptional effect of cytokine target genes. CytoSig therefore provides a significantly more comprehensive analysis of cytokine signaling than the currently used Interferome and GSEA databases.

Technology Overview

Cytokines are a broad category of intercellular signaling proteins that are critical for intercellular communication in human health and disease. Current methods for systematic profiling of cytokine signaling activities are challenging due to: (i) cytokines’ short half-lives; (ii) pleiotropic functions; and (iii) cytokine activity redundancy within specific cellular contexts.  Additionally, existing cytokine signaling target databases only cover a small fraction of cytokines, leaving most cytokine-induced target changes unexplored. 

CytoSig solves these challenges with its significantly larger database content coverage and uses transcriptome data to model cytokine signaling activity and regulatory cascades in human inflammatory processes. CytoSig couples large-scale automatic data processing with natural language processing functions to assist expert metadata annotations with RNA-sequencing (RNA-seq) and MicroArray big-data analysis. CytoSig is therefore, an excellent tool for leveraging big-data resources in public domains to predict clinical outcomes of anticancer therapies that inhibit cytokine signaling. The NCI is seeking parties interested in licensing and/or co-development of this technology.

The NCI is seeking parties interested in licensing and/or co-development of this technology.

Technology Competitive Advantages

  • Integrative framework leveraging public domain big-data resources to identify therapeutic targets
  • Larger, more comprehensive cytokine coverage compared to existing databases
  • Predictions have better associations with clinical outcomes compared to other methods, and therefore can better inform decisions about anti-cytokine therapies in treating inflammatory diseases
  • Not affected by absence of cytokine-producing cells or zero-read counts for ligand or receptor genes in single-cell transcriptomics analysis

Why attend?

  • Assess co-development and/or licensing interest in this technology
  • Interact with the inventor, ask questions, and provide feedback
  • Learn how to partner with the NCI

Who Should Attend?

  • Business development professionals
  • Drug development professionals
  • Biotech/pharma/academia researchers
  • Investors and entrepreneurs

About the Presenter

Peng Jiang, Ph.D.
Stadtman Investigator
NCI Center for Cancer Research, Cancer Data Science Laboratory

Interested in learning more?

Register for the webinar

Contact us NCITechTransfer@mail.nih.gov

 


TTC Fellowship Opportunities

May 4, 2022

TTC is seeking candidates for three types of Fellowship opportunities: Negotiator, Business Development and Marketing, and Innovation.  Each offer a unique career opportunity within a federal technology transfer office. Learn more including how to apply. 

https://techtransfer.cancer.gov/aboutttc/jointtc

 

 

 


Thank you! Jan. 26th Webinar Highlighting New Covid-19 Diagnostic Technology

January 26, 2022

On January 26th, TTC hosted a webinar entitled "Detection of SARS-CoV-2 and other RNA Virus Using a Novel Improved RT-qPCR Method that Increases Detection Sensitivity and Improves Safety" to highlight a novel Covid-19 diagnostic technology from the National Eye Institute. NEI is seeking partners for collaboration and licensing to accelerate technology development and clinical impact.

If you are interested in learning more, including requesting a copy of the presentation, please reach out to Dr. Joseph Conrad, NCI TTC.

Date and Time

About the Presenter

January 26, 2022
11:00 am - Noon (EST)
Robert B. Hufnagel, M.D., Ph.D.
Chief, Medical Genetics and Ophthalmic Genomics Unit
Chief, Ophthalmic Genomics Laboratory

Technology Overview

DNA or RNA-based diagnostic tests for infectious diseases are critical in modern medicine. In particular, the current gold standard for COVID-19 detection is testing SARS-CoV-2 viral RNA by quantitative reverse transcription Polymerase Chain Reaction (RT-qPCR). The current clinical detection of SARS-CoV-2 involves collection of a patient’s sample with a nasopharyngeal swab or saliva, storage of the sample during transport, extraction of RNA, and detection assay (RT-qPCR). National Eye Institute (NEI) researchers developed a simple preparation method using a chelating resin, which eliminates the RNA extraction step and shortens the overall testing time. Viral detection is similar to the current method with RNA extraction using patient samples. Furthermore, the initial sample heating step inactivates SARS-CoV-2 infectivity, thus improving workflow safety and eliminating the need for a BSL-2 facility. This fast RNA preparation and detection method can be used for a variety of sample types, is safe for clinical staff, and is suitable for standard clinical collection and high-volume testing for both DNA and RNA.

View the technology abstract.

Technology Competitive Advantages

  • Eliminates the RNA extraction step from RT-qPCR
  • Improves safety and ease-of-use
  • Increases test sensitivity
  • Reduces testing time and cost

Why attend?

  • Assess co-development and/or licensing interest in this technology
  • Interact with the inventor, ask questions, and provide feedback
  • Learn how to partner with the NCI

Who Should Attend?

  • Business development professionals
  • Drug development professionals
  • Biotech/pharma/academia researchers
  • Investors and entrepreneurs

Interested in learning more?

Please contact Dr. Joseph Conrad, NCI TTC

 


NCI Tech Opportunity Webinar, November 17

November 4, 2021

Register to join us for an NCI Tech Opportunity Webinar entitled "Use of Tempol as an Antiviral Therapeutic Against COVID-19."

Date: November 17, 2021
Time: 11:00 am - Noon EST
Presenter: Tracey Rouault, M.D., Head, Section on Human Iron Metabolism, NICHD

Hear from NICHD’s Dr. Tracey Rouault about the potential to formulate the compound, Tempol, into a preventative and oral treatment for COVID-19. Tempol prevents the proper function of RNA-dependent RNA polymerase (RdRp) in SARS-CoV-2 by disrupting iron-sulfur (Fe-S) clusters. These Fe-S clusters are necessary for RdRp activity, and the resulting non-functional RdRp prevents replication of the COVID-19 genome. Dr. Rouault will also explain that while Tempol targets Fe-S clusters responsible for COVID-19 replication, it does not affect other cellular processes requiring Fe-S proteins in normal cells. Tempol has the potential to be formulated into an oral antiviral therapeutic for COVID-19.   

Technology Highlights:

  • Small molecule COVID-19 therapeutic
  • Oral delivery
  • Prevents viral replication
  • In vitro and in vivo proof-of-concept
  • Promising safety profile
  • Available for licensing or co-development

Read the technology abstract to learn more

Why attend? 

  • Assess co-development and/or licensing interest in this technology 
  • Interact with the inventor, ask questions, and provide feedback 
  • Learn how to partner with the NCI

Who Should Attend?

  • Business development professionals 
  • Drug development professionals 
  • Biotech/pharma/academia researchers 
  • Investors and entrepreneurs

Email for more information 


NCI Tech Opportunity Webinar:Single Domain Antibodies Targeting SARS-CoV-2 for treating COVID-19

October 1, 2021

TTC technology opportunity webinar on Tuesday, September 28 from 11:00 am - noon, EST. 

Thank you for attending the webinar. Attendees heard from the NCI’s Dr. Mitchell Ho about a potential therapeutic treatment for COVID-19, "Single Domain Antibodies Targeting SARS-CoV2 for Treating Covid-19." There are few therapeutics available for COVID-19 patients that directly target the SARS-CoV-2 novel coronavirus. COVID-19 is caused by SARS-CoV-2, which infects hosts via its spike (S) protein. The S protein contains a receptor binding domain (RBD) that binds to an angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. Dr. Ho’s lab isolated three lead nanobodies, 7A3, 1B5, and 2F7, which were found to be highly effective at blocking RBD-ACE2 binding interactions. This nanobody panel has the potential to block the binding of the S-protein to the ACE2 receptor, thereby preventing SARS-CoV-2 virus from binding to and entering a host cells to cause COVID-19 infection.  

Why attend?

  • Assess co-developing and/or licensing this technology
  • Interact with the inventor, ask questions and provide feedback
  • Learn the advantages of partnering with the NCI

Who should attend?

  • Business development professionals
  • Drug development professionals
  • Biotech/pharma/academic researchers
  • Investors and entrepreneurs

About the featured technology

This technology is pre-clinical with identified lead compounds. It is patent pending and available for licensing or co-development. 

Interested in learning more?

Please contact us NCITechTransfer@mail.nih.gov

 

 


Virtual 2021 Technology Showcase - Thank you for attending

September 2, 2021

 Thank you for attending the virtual Technology Showcase on September 1. 

September 1, 2021 - Save the date

Wednesday, September 1, 2021
11:45 am - 5:15 pm  

See the full agenda here. Follow up with us here.

SPOTLIGHTED TECHNOLOGIES:

  • COVID19 mucosal vaccine studies in rhesus macaques
  • Single Domain Antibodies Targeting SARS-CoV-2 for treating COVID-19
  • Combination Therapy for Prostate and Breast Cancer
  • Antisense Oligonucleotides against Cancer Cell Migration and Invasion 
  • Efficacious Fluorinated Cytidine Analog Cancer Therapeutic with Low Toxicity in Animal Studies
  • The ARE-Del mouse: A novel model for autoimmunity
  • Polymeric Delivery Platform for Therapeutics
  • And more!

ADDITIONAL PANELS:

  • How to tap into the Frederick National Laboratory’s resources
  • Foundations and philanthropies as strategic partners
  • How to work with the National Cancer Institute and the Frederick National Laboratory
  • Government and for-profit funding and resources for startups

WHO SHOULD ATTEND?

  • Life-science / healthcare companies of all sizes
  • Investors, entrepreneurs
  • Technology scouts looking for technologies to commercialize
  • Economic development entities
  • Foundations
  • Interested stakeholders

EVENT OVERVIEW:

  • The 2021 Technology Showcase on September 1 will showcase technologies being developed at the NCI and the FNL to encourage startup company formation, technology licensing and collaborations 
  • Free, half-day virtual event
  • Hear from NCI and FNL inventors about technologies primed for collaboration and/or commercialization
  • Panel sessions focused on technology commercialization
  • Lightning Pitch and Poster session highlighting additional NCI technologies for collaborative development and/or /licensing presented by the NCI Technology Transfer Ambassadors Program

 

     


    Thank you! NCI Tech Opportunities Webinar: New HIV Vaccine to Treat and Prevent HIV

    July 14, 2021

    Thank you for attending the technology opportunity webinar on July 13, 2021.

    If you would like to learn more about this technology, including requesting a copy of the presentation, please reach out to reach out to Dr. Joseph Conrad, NCI TTC

    Attendees heard from the NCI’s Dr. Genoveffa Franchini about a new HIV vaccine with the potential to prevent HIV infection and treat HIV.  The effectiveness of the new vaccine results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is seeking a collaboration partner for the NCI Phase 2 and 3 clinical trials for this vaccine and/or a licensing partner to bring the vaccine to market. Dr. Franchini will also discuss two other NCI technologies that further enhance the vaccine’s effectiveness:

    Why Attend?
    Who should attend?

    • Assess co-developing and/or licensing this technology
    • Interact with the inventor, ask questions and provide feedback
    • Learn how to partner with the NCI

    • Business development professionals
    • Drug development professionals
    • Biotech/pharma/academia researchers
    • Investors and entrepreneurs

      About the vaccine:

      This new vaccine’s effectiveness in macaques results from deletion of the V1 region from gp120, enhancing the immune system’s ability to see and better target the virus’ gp120 V2 region. The NCI is planning a Phase 1 clinical study on this vaccine at the NIH Clinical Center in late 2022.  

      What an HIV Vaccine could mean for patients - potential new standard of care

      Since 1985, the FDA approved 57 HIV therapeutics in seven HIV drug classes.  The current standard of care for treating HIV infection is a daily oral treatment with antiretroviral therapeutics, which are often combined with three other HIV medications selected from at least two different HIV drug classes. 

      An HIV vaccine would completely change the current way HIV infections are addressed.  For uninfected individuals, the HIV vaccine would protect them from contracting the disease. For infected individuals, it would substantially improve their quality of life by:

           • Providing a potential cure, rather than treating symptoms 
           • Eliminating the virus, rather than suppressing it
           • Providing a prime/boost treatment regimen for a finite amount of time, rather than lifelong daily dosing 

      Contact us if you are interested in learning more about this technology: ncitechtransfer@mail.nih.gov

      NCI Technology Opportunities Webinar: “Complete Tumor Regression Seen in Colon Cancer and Leukemia Animal Models with a Novel High Efficacy Fluorinated Cytidine Therapeutic Compound"

      May 8, 2021

      Thank you for attending this webinar on May 7th. If you were unable to attend and are interested in learning more about the featured technology, contact us for more information.


      OVERVIEW:

      The NCI TTC will host a webinar on May 7th to highlight NCI’s novel, therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia. Studies indicated that the therapeutic compound can produce complete regression in xenograph mouse models with minimal effects on body weight.  Registration is free.

      TECHNOLOGY DESCRIPTION

      • Potential therapeutic for various types of cancers – including colon cancer and leukemia
      • Comparative in vivo efficacy study in several human tumor xenograft studies indicated low toxicity and high efficacy vs. gemcitabine.
      • Produced complete tumor regression in colon cancer mouse models with a durable response beyond 150 days
      • Complete tumor regression was observed in a leukemia mouse xenograft model
      • Incorporating fluorine increases lipophilicity through steric and electronic effects.

      TECHNOLOGY COMPETITIVE ADVANTAGES

      • Oral activity
      • Increased lipophilicity blocks cancer cell metabolism and increases agent potency
      • Increased selectivity and decreased toxicity compared to other aza-cytidines

      Doctor Joel Morris, NCIPRESENTER:

      Joel Morris, Ph.D., Chief, Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, National Cancer Institute

      DATE & TIME: 

      May 26, 2021, 11:00am – Noon

      WHY ATTEND:

      • Assess the prospect of potentially licensing this technology.
      • Interact with the inventor, ask questions and provide feedback.
      • Learn how to partner with the NCI

      WHO SHOULD ATTEND:

      • Business development professionals
      • Drug development professionals
      • Biotech/pharma/academia Researchers
      • Investors
      • Entrepreneurs 

       


      Annual Technology Showcase Named Winner of 2021 Federal Laboratory Consortium (FLC) State and Local Economic Development Award

      February 3, 2021

      The FLC, a Congressionally mandated organization that educates, promotes, and facilitates federal technology transfer, announced its selection of NCI’s Annual Technology Showcase for its 2021 State and Local Economic Development Award. The FLC State and Local Economic Development Award recognizes successful initiatives that involve partnership between state or local economic development groups and federal laboratories for economic benefit.

      The Technology Showcase is an annual event created to provide scientists from NCI and the Frederick National Laboratory (FNL) a platform to highlight the commercial and life-saving potential of their discoveries to an audience of potential collaborators and licensees. It was conceived by the NCI Technology Transfer Center, the Frederick National Laboratory’s Partnership Development Office and the NCI Office of Scientific Operations. By hosting it at the FNL, they recognized the opportunity to partner with the economic development offices of the City and County of Frederick and the Technology Development Corporation of Maryland (TEDCO) to leverage their regional knowledge, resources, relationships, and expertise. The organizations agreed on goals and entered into a co-sponsorship agreement.

      The Technology Showcase – now going on its 5th year – centers around NCI and FNL researchers who made business pitches for their technologies to an audience of potential industry collaborators and licensees – in contrast to traditional presentations to a purely scientific audience. In addition, representatives from the NCI Technology Transfer Ambassadors Program – composed of post-doctoral scientists seeking unique professional/career education opportunities – develop and present posters highlighting the commercialization potential of additional NIH technologies. In 2020, the event organizers pivoted their efforts to deliver a virtual event that successfully provided interested parties an opportunity to participate regardless of location. The awareness and outreach provided by the annual Technology Showcase means that stakeholders understand they can turn to NCI and FNL when looking for a subject matter expert for collaboration to overcome a technology hurdle. Importantly, the effort serves to increase the likelihood that potentially life-saving cancer inventions may be developed and have a positive impact for patients.

      Award Recipients:
      NCI TTC:
      Michele Newton, Laura Prestia, Ph.D., Michael Salgaller, Ph.D. and Thomas Stackhouse, Ph.D.
      FNL:
      Victoria Brun, Maryellen Hackett, Vladimir Popov, Ph.D., Maggie Scully, Ph.D.
      NCI Frederick Office of Scientific Operations:
      Walter Hubert, Ph.D.
      Frederick County Department of Economic Development
      Heather Gramm, Helen Propheter
      Frederick City Department of Economic Development
      Mary Ford-Naill, Richard Griffin


      TTC-Hosted Technology Webinar Featured Novel Polymeric Drug Delivery Platform

      January 28, 2021

      TTC hosted a complimentary technology webinar on January 27 from 11:00 am - noon. Dr. Stephan T. Stern of the NCI Nanotechnology Laboratory located at the Frederick National Laboratory discussed his invention: "A Novel Lymphatic/Brain Targeting Macromolecular Prodrug System"

      ABOUT THE TECHNOLOGY

      The invention is a novel polymeric drug delivery platform that targets the lymphatic system and brain through scavenger receptor A1 (SR-A1) mediated transcytosis. The SR-A1 receptor is highly expressed in macrophages, monocytes, mast cells, and dendritic cells (myeloid lineages), and also endothelial cells.
      This platform and lymphatic-targeting polymeric drug delivery system:

      • Can deliver various therapeutic/diagnostic imaging cargo to the brain, as well as to the lymphatic system and myeloid/antigen presenting cell (APC) sub-populations for treatment of various disease states or for tracking response to therapy.
      • Is particularly well suited for delivery of immunomodulatory drugs and delivering cancer therapeutics to the lymphatic environment that metastatic cancer cells use to spread to other parts of the body, including the brain.
      • Can enable prognostics for the lymphatic spread of metastatic cancers and evaluating treatment response

       If you are interested in learning more about this technology, please contact: Joseph.Conrad@nih.gov.

       
       

       

       

       

       

       

       


      Pages